{"entity":{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","aka":[],"tldr":"Antibodies against TIGIT, a brake on T cells and natural killer cells, tested alongside PD-L1 drugs; the biggest lung cancer trials so far have failed.","summary":"TIGIT is an inhibitory receptor on T and natural killer cells that competes with the activating receptor CD226 for the ligand CD155. Tiragolumab (Roche) reached phase 3 with atezolizumab after promising phase 2 results in lung cancer, but the SKYSCRAPER programme did not improve survival, and several rivals paused development. Fc-active and Fc-silent antibodies, and combinations in other tumours, are still being tested.","status":"phase-3","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/TIGIT","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/TIGIT"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["immunotherapy"],"technologies":[],"targets":["tigit"],"drugs":["tiragolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"principle":"Monoclonal antibodies bind TIGIT to stop it engaging CD155, freeing CD226 co-stimulation; Fc-active versions may also deplete regulatory T cells.","strengths":["Complements PD-1/PD-L1 blockade mechanistically","Well tolerated in trials"],"limitations":["Phase 3 lung cancer trials negative","Benefit, if any, confined to undefined subgroups","Fc-format questions unresolved"]},"route":"/technologies/tigit-blockade/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"}],"drug":[{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"}]}}